Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US10793596 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(3 years from now) | |
US8536131 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(3 years from now) | |
US10017536 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(3 years from now) | |
US7727963 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(3 years from now) | |
US7713937 | CARA THERAP | Synthetic peptide amides and dimeric forms thereof |
Nov, 2027
(3 years from now) | |
US7402564 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10138270 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(3 years from now) | |
US8486894 | CARA THERAP | Synthetic peptide amides and dimeric forms thereof |
Nov, 2027
(3 years from now) | |
US9359399 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(3 years from now) | |
US9334305 | CARA THERAP | Synthetic peptide amides and dimers thereof |
Nov, 2027
(3 years from now) | |
US8236766 | CARA THERAP | Uses of synthetic peptide amides |
Nov, 2027
(3 years from now) | |
US8217007 | CARA THERAP | Synthetic peptide amides |
Nov, 2027
(3 years from now) |
Korsuva is owned by Cara Therap.
Korsuva contains Difelikefalin Acetate.
Korsuva has a total of 12 drug patents out of which 0 drug patents have expired.
Korsuva was authorised for market use on 23 August, 2021.
Korsuva is available in solution;intravenous dosage forms.
Korsuva can be used as treatment of moderate-to-severe pruritus associated with chronic kidney disease (ckd-ap) in adults undergoing hemodialysis (hd).
Drug patent challenges can be filed against Korsuva from 23 August, 2025.
The generics of Korsuva are possible to be released after 12 November, 2027.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Aug 23, 2026 |
Drugs and Companies using DIFELIKEFALIN ACETATE ingredient
NCE-1 date: 23 August, 2025
Market Authorisation Date: 23 August, 2021
Treatment: Treatment of moderate-to-severe pruritus associated with chronic kidney disease (ckd-ap) in adults undergoing hemodialysis (hd)
Dosage: SOLUTION;INTRAVENOUS